Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study

Kihyun Kim, MD PhD, Jin Seok Kim, MD PhD, Sung-Soo Yoon, MD PhD, Dok-Hyun Yoon, MD PhD, HyeonSeok Eom, MD PhD, Je-Jung Lee, MD PhD, Hyeonwoo Yim, MD PhD, Misun Park, MS, Hojoon Lee, DRPH,MDMPH,PhD, Chang Ki Min, MD PhD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-136242

Published: 2020

Journal Articles

A Phase I/II Study (JACKPOT8) of DZD4205, a Selective JAK1 Inhibitor, in Refractory or Relapsed Peripheral T- Cell Lymphoma

Won-Seog Kim, Dok-Hyun Yoon, MD PhD, Hyeon-Seok Eom, Youngil Koh, Jae-Yong Kwak, Won-Sik Lee, Jong-Seok Lee, Ho-Jin Shin, Yuqin Song, MD PhD, Haiyan Yang, MD PhD, Mei Wang, Jingrun Li, MDPhD, Xubin Huang, Xueyuan Deng, Kan Chen, Zhenfan Yang, Jun Zhu

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-134650

Published: 2020

Journal Articles

Rituximab-CHOP and Central Nervous System Prophylaxis Using Intrathecal Methotrexate in Primary Breast Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm Phase II Study

Ho-Young Yhim, MD, Cheolwon Suh, Seok Jin Kim, MD PhD, Deok-Hwan Yang, MD PhD, Hyeon-Seok Eom, MD, Kyoung Ha Kim, MD PhD, Yong Park, Jin Seok Kim, MD PhD, Hyo Jung Kim, MD PhD, Dok Hyun Yoon, MD PhD, Won Seog Kim, MD PhD, Jae-Yong Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 4076.

https://doi.org/10.1182/blood-2019-122631

Published: 2019

Journal Articles

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 1585.

https://doi.org/10.1182/blood-2019-123933

Published: 2019

Journal Articles

An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk

Catherine Diefenbach, MD, Sarit Assouline, MD, Francesc Bosch, MD PhD, Chan Y. Cheah, Won Seog Kim, MD PhD, Matthew J Matasar, MD, Carlos Panizo, MD PhD, Dok Hyun Yoon, MD PhD, Brendan Bender, PhD, Genevive Hernandez, PhD, Chi-Chung Li, PhD, Bruce McCall, MD, Carol O'Hear, MD PhD, Michael C Wei, MD PhD, Shen Yin, PhD, Kasra Yousefi, MSc, Antonia Kwan, MD PhD MRCPCH, Loretta J. Nastoupil, MD MSc

Blood (2019) 134 (Supplement_1): 4728.

https://doi.org/10.1182/blood-2019-123757

Published: 2019

Journal Articles

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Ho Sup Lee, MD PhD, Chang-Ki Min, MD PhD, Kihyun Kim, MD, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Sung-Soo Yoon, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, MD PhD, Dok Hyun Yoon, MD PhD, Cheolwon Suh, Ho-Jin Shin, MD PhD, Yeung-Chul Mun, MD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, Hye Jin Kang, MD PhD

Blood (2019) 134 (Supplement_1): 3114.

https://doi.org/10.1182/blood-2019-122404

Published: 2019

Journal Articles

Salvage Autologous Stem Cell Transplantation in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Jaewon Hyung, MD, Jung Yong Hong, Dok Hyun Yoon, MD PhD, Kyoungmin Lee, MD, Shin Kim, RN, Chan-Sik Park, Jooryung Huh, MD PhD, Jin-Sook Ryu, Cheolwon Suh, MD PhD

Blood (2017) 130 (Supplement 1): 5506.

https://doi.org/10.1182/blood.V130.Suppl_1.5506.5506

Published: 2017

Journal Articles

Thiotepa, Busulfan, and Cyclophosphamide and Busulfan, Cyclophosphamide, Etoposide As Autologous Stem Cell Transplantation Conditioning Regimen in Primary Central Nervous System Lymphoma

Jaewon Hyung, MD, Jung Yong Hong, Dok Hyun Yoon, MD PhD, Kyoungmin Lee, MD, Shin Kim, RN, Chan-Sik Park, Jooryung Huh, MD PhD, Jin-Sook Ryu, Cheolwon Suh, MD PhD

Blood (2017) 130 (Supplement 1): 3300.

https://doi.org/10.1182/blood.V130.Suppl_1.3300.3300

Published: 2017

Journal Articles

CD34+ Cell Count and Disease Free Survival in Patients with Diffuse Large B Cell Lymphoma Who Have Received Autologous Stem Cell Transplantaion

Jaejoon KIM, Cheolwon Suh, MD PhD, Jung Yong Hong, Dok Hyun Yoon, MD PhD, Moonho Kim

Blood (2017) 130 (Supplement 1): 5519.

https://doi.org/10.1182/blood.V130.Suppl_1.5519.5519

Published: 2017

Journal Articles

Adding Beta-2 Microglobulin for Better Prognostication of Primary Central Nervous System Lymphoma

Jaewon Hyung, MD, Jung Yong Hong, Dok Hyun Yoon, MD PhD, Kyoungmin Lee, MD, Shin Kim, RN, Chan-Sik Park, Jooryung Huh, MD PhD, Jin-Sook Ryu, Cheolwon Suh, MD PhD

Blood (2017) 130 (Supplement 1): 4139.

https://doi.org/10.1182/blood.V130.Suppl_1.4139.4139

Published: 2017

Journal Articles

Immune Checkpoint (PD-1, PD-L1, PD-L2, and CTLA-4) Expression in Plasma Cell Myeloma

Min Young Lee, MD PhD, Chan-jeoung Park, MD, Young-Uk Cho, Eunkyoung You, Seongsoo Jang, MD, Jung-Hee Lee, MD PhD, Jung Yong Hong, Dok Hyun Yoon, MD PhD, Cheolwon Suh, MD PhD

Blood (2017) 130 (Supplement 1): 4400.

https://doi.org/10.1182/blood.V130.Suppl_1.4400.4400

Published: 2017

Journal Articles

Autologous EBV-Specific T Cells (CMD-003): Early Results from a Multicenter, Multinational Phase 2 Trial for Treatment of EBV-Associated NK/T-Cell Lymphoma

Blood (2017) 130 (Supplement 1): 4073.

https://doi.org/10.1182/blood.V130.Suppl_1.4073.4073

Published: 2017

Journal Articles

A Phase II Study of Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma

Silvia Park, Seok Jin Kim, MD PhD, Jung Yong Hong, Dok Hyun Yoon, MD PhD, Jin Seok Kim, MD PhD, Hye Jin Kang, MD PhD, Hyeon-Seok Eom, Mark Hong Lee, Cheolwon Suh, MD PhD, Won Seog Kim, MD, Ph. D.

Blood (2017) 130 (Supplement 1): 4077.

https://doi.org/10.1182/blood.V130.Suppl_1.4077.4077

Published: 2017

Journal Articles

The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)

Blood (2017) 130 (Supplement 1): 3130.

https://doi.org/10.1182/blood.V130.Suppl_1.3130.3130

Published: 2017

Journal Articles

The Absolute Lymphocyte Count Is Associated with the Prognosis in Patients with Peripheral T-Cell Lymphoma, Not Otherwise Specified

Byeong Seok Sohn, MDPhD, Jeongseok Kim, MD, Dok Hyun Yoon, MD PhD, Shin Kim, RN, Jooryung Huh, MD PhD, Sung-En Park, MD, Young Jin Yuh, MD PhD, Cheolwon Suh, MD PhD

Blood (2017) 130 (Supplement 1): 2803.

https://doi.org/10.1182/blood.V130.Suppl_1.2803.2803

Published: 2017

Journal Articles

the Safety and Efficacy of Pomalidomide in Combination with Cyclophosphamide and Dexamethasone (PCD) in the Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma (MM) Who Had Lenalidomide Plus Dexamethasone (LD) Following Frontline Bortezomib Combined Chemotherapy, Open-Labeled, Multicenter Phase II Study

Ho Sup Lee, MD, Chang-Ki Min, MD PhD, Kihyun Kim, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, Dok Hyun Yoon, MD PhD, Cheolwon Suh, MD PhD, Ho-Jin Shin, MD, Yeung-Chul Mun, MD PhD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, MD PhD, Hye Jin Kang, MD PhD, Sung-Soo Yoon, MD PhD

Blood (2017) 130 (Supplement 1): 1834.

https://doi.org/10.1182/blood.V130.Suppl_1.1834.1834

Published: 2017

Journal Articles

Treatment of Bilateral Synchronous Ocular Adnexa Marginal Zone Lymphoma: Consortium for Improving Survival of Lymphoma (CISL) Study

Sung Yong Oh, Jin Seok Kim, MD PhD, Ji Hyun Lee, MD PhD, Won Seog Kim, MD, Ph. D., Seok Jin Kim, MD PhD, Dok Hyun Yoon, MD PhD, Jung Yong Hong, Won-Sik Lee, MD, Hyo Jung Kim, MD PhD, Jong-Ho Won, MD, Byeong Park, MD, Soon Il Lee, Cheolwon Suh, MD PhD

Blood (2017) 130 (Supplement 1): 5155.

https://doi.org/10.1182/blood.V130.Suppl_1.5155.5155

Published: 2017

Journal Articles

The Efficacy of Systemic High Dose Methotrexate As Central Nervous System Prophylaxis in Patients with High Risk Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Analysis

Kyoungmin Lee, MD, Dok Hyun Yoon, MD PhD, Jung Yong Hong, Jung Bok Lee, PhD, Shin Kim, RN, Jung Sun Park, MSc, Jooryung Huh, MD PhD, Sang Wook Lee, MD, Cheolwon Suh, MD PhD

Blood (2017) 130 (Supplement 1): 4130.

https://doi.org/10.1182/blood.V130.Suppl_1.4130.4130

Published: 2017

Journal Articles

Final Report on Phase II Trial of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (Methotrexate, Ifosfamide, Etoposide, Dexamethasone, and L-asparaginase) Chemotherapy for Patients with Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type

Dok Hyun Yoon, MD PhD, Seok Jin Kim, MD PhD, Seong Hyun Jeong, MD, Dong-Yeop Shin, MD, Sung Hwa Bae, MD, Junshik Hong, MD, Seong Kyu Park, MD, Ho-Young Yhim, MD, Deok-Hwan Yang, MD, Hye Won Lee, MD, Mark Lee, MD PhD, Hyeonseok Eom, MD, PhD, Jae-Yong Kwak, MD PhD, Jae Hoon Lee, Cheolwon Suh, Won Seog Kim, MD PhD

Blood (2015) 126 (23): 3942.

https://doi.org/10.1182/blood.V126.23.3942.3942

Published: 2015

Journal Articles

Efficacy and Safety of Dose Attenuated CHOP Chemotherapy for Peripheral T-Cell Lymphoma in Elderly Patients

Eun-Ji Choi, MD, Dok Hyun Yoon, MD PhD, Chan-Sik Park, Jooryung Huh, Sang-wook Lee, Eun Jin Chae, Jin-Sook Ryu, Cheolwon Suh

Blood (2015) 126 (23): 3953.

https://doi.org/10.1182/blood.V126.23.3953.3953

Published: 2015

NARROW

Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study

A Phase I/II Study (JACKPOT8) of DZD4205, a Selective JAK1 Inhibitor, in Refractory or Relapsed Peripheral T- Cell Lymphoma

Rituximab-CHOP and Central Nervous System Prophylaxis Using Intrathecal Methotrexate in Primary Breast Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm Phase II Study

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Salvage Autologous Stem Cell Transplantation in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Thiotepa, Busulfan, and Cyclophosphamide and Busulfan, Cyclophosphamide, Etoposide As Autologous Stem Cell Transplantation Conditioning Regimen in Primary Central Nervous System Lymphoma

CD34+ Cell Count and Disease Free Survival in Patients with Diffuse Large B Cell Lymphoma Who Have Received Autologous Stem Cell Transplantaion

Adding Beta-2 Microglobulin for Better Prognostication of Primary Central Nervous System Lymphoma

Immune Checkpoint (PD-1, PD-L1, PD-L2, and CTLA-4) Expression in Plasma Cell Myeloma

Autologous EBV-Specific T Cells (CMD-003): Early Results from a Multicenter, Multinational Phase 2 Trial for Treatment of EBV-Associated NK/T-Cell Lymphoma

A Phase II Study of Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma

The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)

The Absolute Lymphocyte Count Is Associated with the Prognosis in Patients with Peripheral T-Cell Lymphoma, Not Otherwise Specified

Treatment of Bilateral Synchronous Ocular Adnexa Marginal Zone Lymphoma: Consortium for Improving Survival of Lymphoma (CISL) Study

The Efficacy of Systemic High Dose Methotrexate As Central Nervous System Prophylaxis in Patients with High Risk Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Analysis

Final Report on Phase II Trial of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (Methotrexate, Ifosfamide, Etoposide, Dexamethasone, and L-asparaginase) Chemotherapy for Patients with Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type

Efficacy and Safety of Dose Attenuated CHOP Chemotherapy for Peripheral T-Cell Lymphoma in Elderly Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only